<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138423</url>
  </required_header>
  <id_info>
    <org_study_id>UMCU-Vasc-14A</org_study_id>
    <nct_id>NCT01138423</nct_id>
  </id_info>
  <brief_title>Treatment of Adiposity Related hypErTension (TARGET)</brief_title>
  <acronym>TARGET</acronym>
  <official_title>A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood pressure (hypertension) is an important cause of myocardial infarction and stroke.&#xD;
      High blood pressure often occurs in people who are overweight. These people frequently also&#xD;
      have abnormal fat and sugar metabolism. The combination of these problems is called the&#xD;
      'metabolic syndrome'.&#xD;
&#xD;
      People with hypertension and obesity currently receive the same drug therapy as people with&#xD;
      hypertension, but without obesity. Different classes of drugs are thought to be equally&#xD;
      effective in lowering blood pressure.&#xD;
&#xD;
      Next to lowering blood pressure, hypertension treatment can have additional effects, like&#xD;
      changes in blood vessel function (the ability to dilate and constrict) or changes is the&#xD;
      metabolism of sugar and fat. Particularly in patients with the metabolic syndrome, these&#xD;
      additional effects are thought to be of great importance, because they can influence the risk&#xD;
      for cardiovascular diseases.&#xD;
&#xD;
      The blood pressure lowering mechanism differs between classes of blood pressure lowering&#xD;
      medication. The purpose of this study is to compare the effects of three types of blood&#xD;
      pressure lowering medication belonging to different classes. The main outcomes of interest&#xD;
      will be blood vessel function (the ability to dilate and constrict) and blood pressure.&#xD;
      Moreover, the effect of treatment on additional outcomes, like metabolism of sugar and fat,&#xD;
      will be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of obesity related hypertension (ORH) is challenging and has become an important&#xD;
      global health problem. According to guidelines, most classes of antihypertensives are equally&#xD;
      effective for the treatment of hypertension. However, these guidelines are based on evidence&#xD;
      from studies in patients with essential hypertension, but without a specific focus on ORH.&#xD;
      There is an increasing body of evidence about the complex pathophysiological mechanisms of&#xD;
      ORH. Adipose tissue dysfunction is commonly regarded as a common soil that eventually causes&#xD;
      up regulation of the sympathetic nervous system (SNS) and the renin-angiotensin-system (RAS).&#xD;
      Moreover, development of hypertension is closely related to development of endothelial&#xD;
      dysfunction, dyslipidemia and disorders of glucose metabolism. The investigators hypothesize&#xD;
      that treatment with antihypertensives that are directed at down regulation of the SNS&#xD;
      (moxonidine) and the RAS (aliskiren) will result in more beneficial effects than treatment&#xD;
      with a diuretic (hydrochlorothiazide), because the latter reduces blood pressure by&#xD;
      inhibition of sodium resorption, without influencing the underlying disease mechanism. The&#xD;
      main outcomes of interest are endothelial function and blood pressure, but many secondary&#xD;
      outcomes are studied too.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function assessed by Flow Mediated Dilation (FMD)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour systolic/diastolic blood pressure Mean day- and night time systolic/diastolic blood pressure</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Blood pressure (estimated with pulse wave analysis)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin-Angiotensin System (RAS) hormone concentrations</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sympathetic nervous system activity, assessed by Muscle Sympathetic Nerve Activity (MSNA) and Heart Rate Variability (HRV)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of oxidative stress (concentrations of F2-isoprostanes in urine and oxLDL in plasma)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation (hs-CRP in plasma)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional sodium excretion</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness (assessed by pulse wave velocity and the pulse wave analysis augmentation index)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue function (serum concentrations of adipokines)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism (serum lipid concentrations)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity, expressed by homeostatic model assessment (HOMA)</measure>
    <time_frame>After 8 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypertension</condition>
  <condition>Abdominal Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Brand name: Ralisez</other_name>
    <other_name>ATC-code: C09XA02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine</intervention_name>
    <description>Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Moxonidine</arm_group_label>
    <other_name>No brand name (generic product)</other_name>
    <other_name>ATC-code: C02AC05</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <other_name>No brand name (generic product)</other_name>
    <other_name>ATC-code: C03AA03</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for aliskiren)</intervention_name>
    <description>Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for moxonidine and hydrochlorothiazide)</intervention_name>
    <description>Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient is a male or post menopausal female, 30-70 years of age on the day of signing&#xD;
             informed consent. Post menopausal status is assumed if a woman has not experienced a&#xD;
             menstrual bleed for a minimum of 12 months, assuming that she still has a uterus, and&#xD;
             is not pregnant or lactating. In women without a uterus, menopause or postmenopause is&#xD;
             defined by a very high FSH level.&#xD;
&#xD;
          -  All patients should fulfil the diagnostic criterion of abdominal adiposity: waist&#xD;
             circumference &gt; 102 cm (men) or &gt; 88 cm (women). The waist circumference is measured&#xD;
             halfway between the lower rib and iliac crest in standing position.&#xD;
&#xD;
          -  All patients should fulfil the diagnostic criterium for hypertension: systolic blood&#xD;
             pressure &gt;/= 130 mmHg and/or diastolic blood pressure &gt;/= 85 mmHg during both visits.&#xD;
             Blood pressure is assessed by office readings in accordance with current guidelines&#xD;
             for hypertension diagnosis. The patient needs to be seated some minutes before and&#xD;
             during the measurement. The cuff size should be adjusted to the patients' arm&#xD;
             circumference and needs to be on the same height level as the patients' sternum during&#xD;
             the measurements. Blood pressure is determined to a 2 mmHg accuracy-level. Blood&#xD;
             pressure is measured on both arms during the first visit. In both measurements differ&#xD;
             more than 10 mmHg, the highest value is taken. After at least 15 seconds, the&#xD;
             measurement is repeated during the same visit. The highest mean of the two&#xD;
             measurements on the same arm is considered as the actual blood pressure value.&#xD;
&#xD;
          -  Patients should fulfil one or more of the following criteria to meet the definition of&#xD;
             the metabolic syndrome: 1)Hypertriglyceridemia (serum triglycerides &gt; 1.7 mmol/L); 2)&#xD;
             Low High-density lipoprotein (HDL)-cholesterol (serum HDL-cholesterol &lt; 1.04 mmol/L&#xD;
             (men) or &lt; 1.29 mmol/L (women)); 3)High fasting glucose (fasting serum glucose &gt; 5.6&#xD;
             mmol/L).&#xD;
&#xD;
          -  Patient understands the study procedures, alternative treatments available, and risks&#xD;
             involved with the study and voluntarily agrees to participate by giving written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg during&#xD;
             one or more screening measurements.&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 35 kg/m2&#xD;
&#xD;
          -  Current smoking or smoking during the previous 3 months&#xD;
&#xD;
          -  Use of &quot;recreational&quot; or illicit drugs&#xD;
&#xD;
          -  Recent history (within the last year) of alcohol abuse or dependence.&#xD;
&#xD;
          -  History of hypersensitivity reactions or intolerance to any (components of) medication&#xD;
             used in this trial.&#xD;
&#xD;
          -  Current / recent participation (within 30 days of signing informed consent) in a study&#xD;
             with an investigational compound or device.&#xD;
&#xD;
          -  Laboratory values as follows: Hemoglobin (Hb) &lt; 8,6 mmol/L (men) or &lt; 7.4 mmol/L&#xD;
             (women); TSH &lt;0.3 mcIU/mL or &gt; 5.0 mcIU/mL; Potassium &lt; 3,8 mmol/L or &gt; 5,0 mmol/L;&#xD;
             Sodium &lt; 136 mmol/L or &gt; 146 mmol/L; MDRD &lt; 60 mL/min/1,73m2&#xD;
&#xD;
          -  Medical conditions as follows: Resistant hypertension (blood pressure above target&#xD;
             level, despite 3 antihypertensives, including a diuretic); Secondary hypertension;&#xD;
             Congestive Heart Failure; Atherosclerotic vascular disease (As per NCEP ATP III and&#xD;
             AHA/ACC Guidelines); Cardiac arrhythmia's, for example bradycardia, atrial&#xD;
             fibrillation, sick-sinus syndrome, sinoatrial block, atrioventricular block or any&#xD;
             other arrhythmia; Obstructive sleep apnea syndrome (OSAS) or a score of 10 or higher&#xD;
             on the Epworth Sleepiness Scale questionnaire; Serious liver function disorders&#xD;
             (Child-Pugh-Class C); COPD (GOLD classification of severity 2 or higher); Celiac&#xD;
             disease or other significant intestinal malabsorption; Malignancy â‰¤ 5 years prior to&#xD;
             signing informed consent, except for adequately treated basal or squamous cell skin&#xD;
             cancer or in situ cervical cancer; Mental instability or major psychiatric illness;&#xD;
             Polyneuropathy or clinical suspicion for autonomic nervous system dysfunction; Any&#xD;
             diseases that would limit or complicate study evaluation or participation; Any&#xD;
             diseases or screening abnormalities that call for treatment that can not be postponed&#xD;
             until after the study period without causing harm.&#xD;
&#xD;
          -  Any concomitant medication, particularly antihypertensive co-medication, glucose&#xD;
             lowering medication, lipid lowering drugs, systemic corticosteroids, birth control&#xD;
             pills and vitamin C or E supplements, but also any other kinds of drugs, including&#xD;
             over the counter medication. Exceptions can be made for the following categories of&#xD;
             drugs: paracetamol; proton-pump inhibitors; topical creams and unguents that do not&#xD;
             lead to uptake of any of the active components into the circulation (in case of&#xD;
             steroid creams: class II or lower); inhalation medication, nasal sprays and eye drops&#xD;
             that do not lead to uptake of any of the active components into the circulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F.L.J. Visseren, Professor (MD PhD)</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. Spiering, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>February 23, 2012</last_update_submitted>
  <last_update_submitted_qc>February 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2012</last_update_posted>
  <responsible_party>
    <name_title>dr. W. Spiering</name_title>
    <organization>University Medical Center Utrecht</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Metabolic Syndrome X</keyword>
  <keyword>Obesity</keyword>
  <keyword>Adiposity</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

